PLEASANTON, Calif., Dec. 18, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that its female first wearable, the Evie Ring, is now eligible for HSA/FSA fund reimbursement.

"Securing eligibility for HSA/FSA fund reimbursement is tantamount to our goal of making the Evie Ring accessible to as many women as possible," said John Mastrototaro, CEO of Movano Health. "We are thrilled to be able to offer consumers an easier way to access a solution that can elevate their overall health and well being."

On average, using HSA/FSA pre-tax dollars can save consumers upwards of 30-50% on qualifying direct to consumer health and wellness purchases. US consumers contribute an estimated $150B into HSA/FSA accounts every year. By meeting these compliance and eligibility standards, the Evie Ring will now be able to serve an even larger population of women.

Movano Health successfully launched the Evie Ring on November 20, 2023 and will be showcasing the solution at CES 2024, where it has been named a CES Innovation Award Honoree in Wearables. The Evie Ring can be purchased exclusively at www.eviering.com.

About Movano Health  

Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes.  For more information on Movano Health, visit https://movanohealth.com/.

Forward Looking Statements

This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to commercial launch of the Evie Ring; planned cost-cutting initiatives; anticipated FDA clearance for the Evie Ring and other products in development; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors."  Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.